Please login to the form below

opicapone

This page shows the latest opicapone news and features for those working in and with pharma, biotech and healthcare.

Neurocrine bags FDA approval for first tardive dyskinesia drug

The company fleshed out its movement disorder pipeline earlier this year by licensing opicapone from Portuguese drug maker BIAL.

Latest news

EC approves Bial’s Parkinson’s disease therapy

Manufactured by Bial, Ongentys (opicapone) is indicated as adjunctive therapy to preparations of levodopa/DOPA decarboxylase inhibitors (DDCIs) in adults with Parkinson's and end-of-dose motor fluctuations who cannot ... Opicapone is a third-generation
Chasing the cure for Parkinson's disease

Opicapone (Bial) is a COMT inhibitor in phase III development in various European countries for the treatment of idiopathic Parkinson's. ... Bial plans to develop opicapone to be administered in combination with levodopa/carbidopa or

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

Deal Watch February 2017

Royalty monetisation. 150. BIAL/ Neurocrine Biosciences. ONGENTYS (opicapone), COMT inhibitor for Parkinson's disease (approved in EU).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Digital Account Director – Health/ Pharma – Global Agency: Salary TBC

Account Director, Healthcare Advertising Agency: Salary TBC

Market Access Consultant - Greater Manchester: Negotiable

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Account Director or Senior Account Director: Salary TBC

Integrated Brand/ Digital Senior Account Director, London: Excellent package

Senior Strategist/ Planner, Healthcare Marketing, London: Excellent package

Graduate Scientific Editor: DOE

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Senior Medical Writer, Principal Medical Writer, Scientific Dire...: £40000 - £75000 Bonus Benefits

Sudler London - Senior Medical Writer: Competitive

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Senior Training Manager - Surrey: Competitive Salary &Bonus

Medical Writers Required - Hertfordshire: Competitive

Associate Scientific Director: Salary TBC

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Senior Account Manager – Healthcare Advertising: Salary TBC

Senior Medical Writer: Salary is DOE

Account Manager- 4 days per week or full-time: Salary TBC

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Senior Writer, Healthcare Advertising, London: Excellent package

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Subscribe to our email news alerts

PMHub

Add my company

Ashfield

Transforming healthcare outsourcing. From small beginnings in 1997, Ashfield has grown rapidly into an international healthcare services organisation. By anticipating...

Latest intelligence

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....